June 5, 2024 4:56pm

A positive sector session closes after starting in the hole followed Tuesday’s down and Monday’s positive session close

Uncle algo and his electronic trading dwarfs are cashing into the till  

I say today what others won't, so you can do what others can't!

Never leave an investor uninformed! 

I follow the dictum, quoting Churchill that “short words are best, and the old words when short are best of all.”

I answer or qualify the sector’s equity’s share pricing mobility; with an emphasis on which company is gaining or losing stride in your portfolio for the short and near-term

 

Wednesday: The Dow closed UP +96.02 points or +0.25%, the S&P closed UP +62.69 points or +1.18% while the Nasdaq closed UP +330.86 points or +1.96%

 

Henry’omics:

We need to more than consider the economic environment - rising rates and inflation to comprehend the micro re “our” universe of cell and gene therapy companies …

Indexes closed up after being down following a little weak labor market data gave investors hope the Fed might move to lower interest rates later this year.

Wednesday’s rally was narrow as some investors worry that weak economic data could signal a broader slowdown.

Economic Data Docket: ADP reported that companies added 152,000 jobs in May, fewer than the downwardly revised 188,000 in April and below consensus estimate for 175,000.

  • May ISM Services PMI topped expectations, coming in at 53.8 against the expected 51.

 

RegMed Investors’ (RMi) pre-open post: “never squat with your spurs on. Another way of saying, don't do buying/selling without thinking or tracking RMi’s post/updates; keep a buy ticket in one hand and a finger on the sell button.” … https://www.regmedinvestors.com/articles/13487

 

Advance/Decline (A/D) Line:

Wednesday’s advance/decline line at the open was negative with 11 incliner, 21 decliners and 3 flats; ending with a positive close of 24 incliners, 9 decliners and 3 flats

 

Ebb and flow of MY covered sector cell and gene therapy session daily “endings”:

  • June: 2 positive and 1 negative closes
  • May: 1 holiday, 11 positive and 11 negative closes
  • April: 16 negative and 6 positive closes

 

Key Metrics:

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

  • Wednesday, the IBB was up +1.90% and the XBI was up +3.24%

The CBOE Volatility Index (VVIX: INDEX) tracked:

  • Wednesday was down -0.50 point or -3.80% at 12.66.

 

Wednesday’s Closing Down (9 of 9):

  • Mesoblast MESO -$0.30 after Tuesday’s +$0.20 and Monday’s -$0.06),
  • Ionis Pharmaceuticals (IONS -$0.18 after Tuesday’s +$1.28 and Monday’s +$1.20),
  • Intellia Therapeutics (NTLA -$0.16 after Tuesday’s -$0.27 and Monday’s +$2.14),
  • Editas Medicine (EDIT -$0.15 after Tuesday’s +$0.34),
  • Solid Biosciences (SLDB -$0.08 after Tuesday’s -$0.40),
  • Compass Therapeutics (CMPX -$0.05),
  • Caribou Biosciences (CRBU -$0.045),
  • bluebird bio (BLUE -$0.021),
  • Brainstorm Cell Therapeutics (BCLI -$0.0028),

Flat (3):

  • Bellicum Pharmaceuticals (BLCM) – dropped)
  • Harvard Apparatus RT (OTCQB: HRGN – its 12th flat sessions)
  • Homology Medicine (FIXX) – under $1.00

Wednesday’s Closing Up (10 of 24):

  • Blueprint Medicine (BPMC +$3.93 after Tuesday’s -$2.95 after Monday’s -$0.72),
  • Alnylam Pharmaceuticals (ALNY +$2.30 after Tuesday’s -$0.69 after Monday’s +$2.02),
  • Lenz Therapeutics (LENZ +$1.45 after Tuesday’s -$0.40 after Monday’s -$0.21),
  • CRISPR Therapeutics (CRSP +$1.44 after Tuesday’s +$1.12 after Monday’s +$3.41),
  • Vericel (VCEL +$0.88 after Tuesday’s -$0.38 after Monday’s -$1.35),
  • BioLife Solutions (BLFS +$0.63 after Tuesday’s -$0.35 after Monday’s -$0.22),
  • Ultragenyx Pharmaceuticals (RARE +$0.53),
  • Sage Therapeutics (SAGE +$0.29 after Tuesday’s -$0.43),
  • Regenxbio (RGNX +$0.20 after Tuesday’s -$0.44 after Monday’s +$0.41),
  • Voyager Therapeutics (VYGR +$0.19),

 

Q2/24 – June

  • Wednesday closed positive with 24 incliners, 9 decliners and 3 flats
  • Tuesday closed negative with 13 incliners, 19 decliners and 3 flats
  • (6/3) Monday closed positive with 18 incliners, 14 decliners and 3 flats

 

The BOTTOM LINE: “Attention remains laser-focused on week’s busy economic calendar; there’s still a bit of hesitation in front of jobs data to really see the reality of the markets and the cell and gene therapy sector’s ability or capacity to STAY upward.” <me>

  • Wednesday, the cell and gene therapy sector return to the upside after popping the bed in decline on Tuesday as investors weighed signs the US economy might be starting to show cracks.

 

Reiterating, “Net-net I am still expecting a bumpy ride for US equities as we stride through the month of June.”

 

The top three (3) performing in the session:  

  • Wednesday: Blueprint Medicine (BLMC), Lenz Therapeutics (LENZ) and CRISPR Therapeutics (CRSP),
  • Tuesday: CRISPR Therapeutics (CRSP), Ionis Pharmaceuticals (IONS) and Mesoblast (MESO)
  • Monday: CRISPR Therapeutics (CRSP), Intellia Therapeutics (NTLA) and Alnylam Pharmaceuticals (ALNY),

The worst three (3) in the session:  

  • Wednesday: Mesoblast (MESO), Intellia Therapeutics (NTLA) and Ionis Pharmaceuticals (IONS)
  • Tuesday: Blueprint Medicine (BLMC), BioLife Solutions (BLFS) and Lenz Therapeutics (LENZ)
  • Monday: Blueprint Medicine (BLMC), Vericel (VCEL) and Caribou Biosciences (CRBU)

Welcome to my world of defining the “grey’ in our universe!

  • Right up front, “I also hate to be so negative or contrarian but, this is a NO spin zone and facts are its product; I can always be WRONG but … I am mostly EARLY!”

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad, or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor, and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication. Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities.

I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.